Cormorant Asset Management, LP - Jan 9, 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role: 10%+ Owner
Signature: /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner
Stock symbol: EYPT
Transactions as of: Jan 9, 2024
Transactions value $: $17,051,100
Form type: 4
Date filed: 1/11/2024, 04:00 PM
Previous filing: Dec 12, 2023
Next filing: Jan 30, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EYPT	Common Stock	Purchase	$2.24M	+105K	+1.74%	$21.32	6.14M	Jan 9, 2024	See Footnote	F1, F2
transaction	EYPT	Common Stock	Purchase	$14.8M	+750K	+12.21%	$19.75	6.89M	Jan 11, 2024	See Footnote	F1

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F2	Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $20.90 to $21.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

Content

Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $20.90 to $21.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.